Abstract
Sustained maintenance of therapeutic levels of angiostatic proteins in tumor tissues continues to represent a major challenge to antiangiogenesis therapy of cancer. In this study, we tested the hypothesis of utilizing gene transfer via replication-competent retroviral (RCR) vectors for chronic protein delivery. We now show that bioactive human interferon-inducible protein-10 (IP10) can be secreted from a variety of mammalian cells upon transduction with RCR vectors carrying the human IP10 gene. The production of IP10 from RCR-transduced cells could be maintained for at least three months in culture. The level and duration of IP10 expression in vivo was sufficient to inhibit growth of subcutaneous (s.c.) tumors as well as metastatic lesions in mice. This tumor inhibition was correlated to a marked reduction in tumor vascularization and mitotic activity. By conducting immunohistological studies, we have been able to show that IP10 vector-affected tumors evidenced elevated levels of IL-12p35 mRNA, with no sign of changes in the local inflammatory response, however, as determined by macrophage infiltration and the expression of proinflammatory cytokines. We are addressing the feasibility of using RCR vector-based gene therapy as a more convenient alternative tool to chronically deliver antiangiogenic proteins for cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman J . Tumor angiogenesis. In: Holland JF, et al, (eds.), Cancer Medicine. 5th ed. Hamilton, Ontario, Canada: Decker; 2000: 132–152.
Folkman J . Fundamental concepts of the angiogenic process. Curr Mol Med. 2003;3:643–651.
Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364.
Hanahan D, Weinberg RA . The hallmarks of cancer. Cell. 2000;100:57–70.
Kerbel R, Folkman J . Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727–739.
Liau G, Su EJ, Dixon KD . Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches. DDT. 2001;6:689–697.
Eatock MM, Schatzlein A, Kaye SB . Tumor vasculature as target for anticancer therapy. Cancer Treat Rev. 2000;26:191–204.
Tennnat TR, Rinker-Schaeffer CW, Stadler WM . Angiogenesis inhibitors. Curr Oncol Rep. 2000;2:11–16.
Feldman AL, Libutti SK . Progression in antiangiogenic gene therapy of cancer. Cancer. 2000;89:1181–1194.
Folkman J . Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15–18.
Zlotnik A, Yoshie O . Chemokines: a new classification system and their role in imunity. Immunity. 2000;12:121–127.
Baggiolini M, Dewald B, Moser B . Human chemokines: an update. Annu Rev Immunol. 1997;15:675–705.
Moore BB, Arenberg DA, Addison CL, Keane MP, Polverini PJ, Strieter RM . CXC chemokines mechanism of action in regulating tumor angiogenesis. Angiogenesis. 1998;2:123–134.
Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM . CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1–8.
Frederick MJ, Clayman GL . Chemokines in cancer. Expert Rev Mol Med. 2001;3:1–18.
Wang JM, Deng X, Gong W, Su S . Chemokines and their role in tumor growth and metastasis. J Immunol Methods. 1998;220:1–17.
Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270:27348–27357.
Luster AD, Greenberg SM, Leder P . The IP10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor-4 and inhibits endothelial cell proliferation. J Exp Med. 1995;182:219–231.
Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 1995;182:155–162.
Luster AD, Leder P . IP10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med. 1993;178:1057–1065.
Pertl U, Luster AD, Varki NM, et al. IFN-γ-inducible protein-10 is essential for the generation of protective tumor-specific CD8T cell response induced by single-chain IL-12 gene therapy. J Immunol. 2001;166:6944–6951.
Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996;184:963–969.
Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Th1 lymphocytes. Nature. 1998;391:344–345.
Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101:746–754.
Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral co-injection of two adenoviruses, one encoding the chemokine IFN-g-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol. 2000;164:3112–3122.
Regulier E, Paul S, Marigliano M, et al. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther. 2001;8:45–54.
Feldman AL, Friedl J, Lans TE, et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer. 2002;99:149–153.
Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA. 2001;98:4605–4610.
Feldman AL, Alexander HR, Hewitt SM, et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst. 2001;93:1014–1020.
Anderson WF . Hum Gene Ther. 1998;392:25–30.
Kay MA, Glorioso JC, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33–40.
Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N . A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther. 2001;12:921–932.
Solly SK, Trajcevski S, Frisen C, et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 2003;10:30–39.
Finger C, Sun Y, Sanz L, Alvarez-Vallina L, Buchholz CJ, Cichutek K . Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. Cancer Gene Ther. 2005;12:464–474.
Buchholz CJ, Peng KW, Morling FJ, Zhang J, Cosset FL, Russell SJ . In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol. 1998;16:951–954.
Schneider RM, Medvedovska Y, Hartl I, et al. Directed evolution of retroviruses activatable by tumor-associated matrix metalloproteases. Gene Therapy. 2003;10:1370–1380.
Moller P, Moller H, Sun Y, et al. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Cancer Gene Ther. 2000;7:976–984.
Weidner N, Semple JP, Welch WR, Folkman J . Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.
Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545.
Bingle L, Brown NJ, Lewis CE . The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol. 2002;196:254–265.
Coussens LM, Werb Z . Inflammation and cancer. Nature. 2002;420:860–867.
Folkman J . Angiogenesis inhibitors. Cancer Biol Ther. 2003;2(Suppl. 1):S127–S133.
Sgadari C, Angiolillo AL, Cherney BW, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA. 1996;93:13791–13796.
Arenberg DA, Kunkel SL, Polverini PJ, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med. 1996;184:981–992.
Farber JM . Mig and IP10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997;61:246–257.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A . Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187:875–883.
Carmeliet P, Jain RK . Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257.
Hartl I, Schneider RM, Sun Y, et al. Library based selection of retroviruses selectively spreading through matrix metalloprotease positive cells. Gene Therapy. 2005, in press.
Logg CR, Logg A, Matusik RJ, Bochner BH, Kasahara N . Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J Virol. 2002;76:12783–12791.
Tai CK, Logg CR, Park JM, Anderson WF, Press MF, Kasahara N . Antibody-mediated targeting of replication-competent retroviral vectors. Hum Gene Ther. 2003;14:789–802.
Acknowledgements
We are grateful to P Volkers for help with statistic analysis, C Coulibaly and R Plesker for help in animal handling, K Boller for expert microscopic imaging, and to J Medvedovska for excellent technical assistance. This work was supported by Grant 2002.067.1 of the Wilhelm-Sander-Stiftung to CJB and KC.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Cancer Gene Therapy website (http://www.nature.com/cgt)
Supplementary information
Rights and permissions
About this article
Cite this article
Sun, Y., Finger, C., Alvarez-Vallina, L. et al. Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 12, 900–912 (2005). https://doi.org/10.1038/sj.cgt.7700854
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700854
Keywords
This article is cited by
-
Heparanase enhances myeloma progression via CXCL10 downregulation
Leukemia (2014)
-
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
Leukemia (2011)
-
Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors
Nature Methods (2010)
-
Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy
Cancer Immunology, Immunotherapy (2010)
-
Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors
BMC Molecular Biology (2009)